

Giuseppe Bronte

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3499606/publications.pdf>

Version: 2024-02-01

116
papers

2,986
citations

159585

30
h-index

197818

49
g-index

119
all docs

119
docs citations

119
times ranked

5664
citing authors

#	ARTICLE	IF	CITATIONS
1	PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. <i>Oncotarget</i> , 2016, 7, 19738-19747.	1.8	134
2	Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. <i>Cancer Treatment Reviews</i> , 2010, 36, S21-S29.	7.7	128
3	Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 129, 35-40.	2.0	122
4	The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, S103-S109.	3.4	117
5	Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis. <i>PLoS ONE</i> , 2015, 10, e0133488.	2.5	110
6	Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?. <i>Cancer Treatment Reviews</i> , 2010, 36, S56-S61.	7.7	103
7	Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non small cell lung cancer. <i>Journal of Cellular Physiology</i> , 2013, 229, n/a-n/a.	4.1	96
8	Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 150-157.	4.4	81
9	Stabilizing versus Destabilizing the Microtubules: A Double-Edge Sword for an Effective Cancer Treatment Option?. <i>Analytical Cellular Pathology</i> , 2015, 2015, 1-19.	1.4	80
10	New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?. <i>Oncotarget</i> , 2015, 6, 24780-24796.	1.8	77
11	Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. <i>Cancer Treatment Reviews</i> , 2014, 40, 990-1004.	7.7	70
12	Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 89, 300-313.	4.4	68
13	Multidisciplinary management of patients with liver metastasis from colorectal cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 7215.	3.3	67
14	Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future. <i>Frontiers in Oncology</i> , 2019, 9, 1519.	2.8	61
15	What links BRAF to the heart function? new insights from the cardiotoxicity of BRAF inhibitors in cancer treatment. <i>Oncotarget</i> , 2015, 6, 35589-35601.	1.8	57
16	The Long and Winding Road to Useful Predictive Factors for Anti-EGFR Therapy in Metastatic Colorectal Carcinoma: The KRAS/BRAF Pathway. <i>Oncology</i> , 2009, 77, 57-68.	1.9	49
17	Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs. <i>Journal of Clinical Medicine</i> , 2020, 9, 1047.	2.4	47
18	MicroRNAs in colorectal cancer stem cells: new regulators of cancer stemness?. <i>Oncogenesis</i> , 2012, 1, e32-e32.	4.9	45

#	ARTICLE	IF	CITATIONS
19	Cancer and the microbiome: potential applications as new tumor biomarker. Expert Review of Anticancer Therapy, 2015, 15, 317-330.	2.4	45
20	Progress with palbociclib in breast cancer: latest evidence and clinical considerations. Therapeutic Advances in Medical Oncology, 2017, 9, 83-105.	3.2	45
21	Germline copy number variation in the <i>YTHDC2</i> gene: does it have a role in finding a novel potential molecular target involved in pancreatic adenocarcinoma susceptibility?. Expert Opinion on Therapeutic Targets, 2014, 18, 841-850.	3.4	44
22	ALK and crizotinib: after the honeymoon what else? Resistance mechanisms and new therapies to overcome it. Translational Lung Cancer Research, 2014, 3, 250-61.	2.8	44
23	Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy. Expert Opinion on Drug Safety, 2015, 14, 253-267.	2.4	43
24	Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: there is a sense in antisense?. Expert Opinion on Therapeutic Targets, 2013, 17, 1249-1261.	3.4	41
25	Targeting RET-rearranged non-small-cell lung cancer: future prospects. Lung Cancer: Targets and Therapy, 2019, Volume 10, 27-36.	2.7	40
26	Bortezomib: A New Pro-Apoptotic Agent in Cancer Treatment. Current Cancer Drug Targets, 2010, 10, 55-67.	1.6	37
27	Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus. Oncotarget, 2016, 7, 47821-47830.	1.8	36
28	Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors. , 2018, 192, 65-73.		35
29	Sex Steroids, Carcinogenesis, and Cancer Progression. Annals of the New York Academy of Sciences, 2004, 1028, 233-246.	3.8	34
30	Hypoxia and Human Genome Stability: Downregulation of BRCA2 Expression in Breast Cancer Cell Lines. BioMed Research International, 2013, 2013, 1-8.	1.9	32
31	Oral Metronomic Vinorelbine in Advanced Non-small Cell Lung Cancer Patients Unfit for Chemotherapy. Anticancer Research, 2018, 38, 3689-3697.	1.1	32
32	The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?. Critical Reviews in Oncology/Hematology, 2016, 107, 20-32.	4.4	31
33	TMB in NSCLC: A Broken Dream?. International Journal of Molecular Sciences, 2021, 22, 6536.	4.1	31
34	HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma. Critical Reviews in Oncology/Hematology, 2016, 97, 312-321.	4.4	30
35	Prognostic significance of <i>K-Ras</i> mutation rate in metastatic colorectal cancer patients. Oncotarget, 2015, 6, 31604-31612.	1.8	30
36	EGFR genomic alterations in cancer prognostic and predictive values. Frontiers in Bioscience - Elite, 2011, E3, 879-887.	1.8	29

#	ARTICLE	IF	CITATIONS
37	HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditions. <i>Breast Cancer Research and Treatment</i> , 2013, 140, 505-517.	2.5	29
38	Sorafenib for the treatment of breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 621-630.	1.8	29
39	BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1081-1088.	4.1	28
40	The role of targeted therapy for gastrointestinal tumors. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 875-885.	3.0	27
41	What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 306-317.	4.4	27
42	Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1173-1187.	2.4	25
43	Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?. <i>BMC Cancer</i> , 2018, 18, 348.	2.6	25
44	Dietary restriction: could it be considered as speed bump on tumor progression road?. <i>Tumor Biology</i> , 2016, 37, 7109-7118.	1.8	24
45	Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases?. <i>Translational Oncology</i> , 2018, 11, 950-956.	3.7	24
46	Epithelial-to-mesenchymal transition in the context of epidermal growth factor receptor inhibition in non-small cell lung cancer. <i>Biological Reviews</i> , 2018, 93, 1735-1746.	10.4	23
47	The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy. <i>Cancers</i> , 2022, 14, 1143.	3.7	23
48	Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1553-1566.	3.1	22
49	Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 615-623.	2.4	21
50	Nintedanib in NSCLC: evidence to date and place in therapy. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 188-197.	3.2	19
51	Advances in Molecular Mechanisms and Immunotherapy Involving the Immune Cell-Promoted Epithelial-to-Mesenchymal Transition in Lung Cancer. <i>Journal of Oncology</i> , 2019, 2019, 1-11.	1.3	19
52	Targeted Therapies in Hepatocellular Carcinoma. <i>Current Medicinal Chemistry</i> , 2014, 21, 966-974.	2.4	19
53	Monoclonal antibodies in gastrointestinal cancers. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 889-900.	3.1	18
54	A headlight on liquid biopsies: a challenging tool for breast cancer management. <i>Tumor Biology</i> , 2016, 37, 4263-4273.	1.8	18

#	ARTICLE	IF	CITATIONS
55	Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor. Expert Opinion on Biological Therapy, 2014, 14, 15-26.	3.1	17
56	Role of liquid biopsy in oncogene-addicted non-small cell lung cancer. Translational Lung Cancer Research, 2019, 8, S265-S279.	2.8	17
57	Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis. Oncotarget, 2016, 7, 69412-69419.	1.8	17
58	Anti-endothelin drugs in solid tumors. Expert Opinion on Emerging Drugs, 2010, 15, 27-40.	2.4	16
59	Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma. Oncotarget, 2016, 7, 21259-21271.	1.8	16
60	HER2-positive male breast cancer: an update. Breast Cancer: Targets and Therapy, 2010, 2, 45.	1.8	15
61	Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors. Expert Opinion on Biological Therapy, 2011, 11, 1433-1445.	3.1	15
62	Analysis of Germline Gene Copy Number Variants of Patients with Sporadic Pancreatic Adenocarcinoma Reveals Specific Variations. Oncology, 2013, 85, 306-311.	1.9	15
63	How to find the Ariadne's thread in the labyrinth of salvage treatment options for metastatic colorectal cancer?. Expert Opinion on Biological Therapy, 2014, 14, 743-748.	3.1	15
64	Predicting Efficacy and Toxicity in the Era of Targeted Therapy: Focus on Anti-EGFR and Anti-VEGF Molecules. Current Drug Metabolism, 2011, 12, 944-955.	1.2	15
65	High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis. Frontiers in Immunology, 2022, 13, 866561.	4.8	15
66	New generation anaplastic lymphoma kinase inhibitors. Translational Lung Cancer Research, 2019, 8, S280-S289.	2.8	14
67	Are There Differences in Androgen Receptor Expression in Invasive Breast Cancer in African (Tanzanian) Population in Comparison With the Caucasian (Italian) Population?. Frontiers in Endocrinology, 2018, 9, 137.	3.5	13
68	Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients?. Translational Oncology, 2022, 15, 101300.	3.7	11
69	Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer?. Journal of Oncology, 2019, 2019, 1-6.	1.3	10
70	Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement. Lung Cancer, 2020, 142, 47-50.	2.0	10
71	Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience. Biomedicines, 2021, 9, 1299.	3.2	10
72	The Role of cMet in Non-Small Cell Lung Cancer Resistant to EGFRInhibitors: Did We Really Find the Target?. Current Drug Targets, 2014, 15, 1284-1292.	2.1	10

#	ARTICLE	IF	CITATIONS
73	Well-Being among Italian Medical Oncologists: An Exploratory Study. <i>Oncology</i> , 2014, 86, 72-78.	1.9	9
74	Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma. <i>Frontiers in Pharmacology</i> , 2021, 12, 672233.	3.5	9
75	The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status. <i>Oncotarget</i> , 2016, 7, 35803-35812.	1.8	9
76	Dilemma in metastatic colorectal cancer: VEGF versus EGFR targeting. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 869-871.	3.4	8
77	The molecular changes driving the carcinogenesis in Barrett's esophagus: Which came first, the chicken or the egg?. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 86, 278-289.	4.4	8
78	Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 45-59.	3.1	8
79	Anti-angiogenic drugs for second-line treatment of NSCLC patients: just new pawns on the chessboard?. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1-5.	3.1	8
80	Epithelial-to-mesenchymal transition and EGFR status in NSCLC: the role of vimentin expression. <i>Annals of Oncology</i> , 2019, 30, 339-340.	1.2	8
81	A Phase II Trial of Fixed-Dose Rate Gemcitabine plus Capecitabine in Metastatic/Advanced Biliary Tract Cancer Patients. <i>Oncology</i> , 2012, 82, 75-82.	1.9	7
82	The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a <i>post hoc</i> analysis of the IBIS 3 trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883591988899.	3.2	7
83	Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy?. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 103-114.	3.1	6
84	Targeted Therapies in Hepatocellular Carcinoma. <i>Current Clinical Pathology</i> , 2015, , 137-145.	0.0	6
85	Farletuzumab for NSCLC: exploiting a well-known metabolic pathway for a new therapeutic strategy. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 125-132.	4.1	5
86	Semi-automated volumetric analysis in the NELSON trial for lung cancer screening: is there room for diagnostic experience yet?. <i>Journal of Thoracic Disease</i> , 2016, 8, E1490-E1492.	1.4	4
87	The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 669839.	2.8	4
88	Targeted Therapies in Melanoma. <i>Current Clinical Pathology</i> , 2015, , 211-227.	0.0	4
89	Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward. <i>Gastroenterology Research and Practice</i> , 2015, 2015, 1-9.	1.5	3
90	High-dose chemotherapy in a patient with coronavirus disease (COVID-19). <i>European Journal of Cancer</i> , 2020, 136, 130-131.	2.8	3

#	ARTICLE	IF	CITATIONS
91	Ramucirumab and its use in gastric cancer treatment. <i>Drugs of Today</i> , 2014, 50, 613.	1.1	3
92	The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 772216.	3.7	3
93	What to look for in cell-free DNA from breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 199-200.	2.5	2
94	Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2021, 12, 672219.	4.8	2
95	Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 809-817.	2.4	2
96	Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients. <i>Cancers</i> , 2022, 14, 2352.	3.7	2
97	The application of cancer stem cell model in malignant mesothelioma. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 174, 103698.	4.4	2
98	Management of Toxicity Induced by Anti-EGFR Therapy in Metastatic Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2013, 9, 250-260.	0.5	1
99	Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines for the adjuvant treatment of early breast cancer?. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 767-768.	2.5	1
100	Fully Human Antibodies for Malignant Pleural Mesothelioma Targeting. <i>Cancers</i> , 2020, 12, 915.	3.7	1
101	Is androgen receptor useful to predict the efficacy of anti-estrogen therapy in advanced breast cancer?. <i>Journal of Clinical Oncology</i> , 2017, 35, 1042-1042.	1.6	1
102	The prognostic role of progesterone receptor in patients with rapidly proliferating, hormone receptor-positive early breast cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 545-545.	1.6	1
103	How Much of Familial Breast Cancer Risk is Currently Explained by the Known Genes?. <i>Current Women's Health Reviews</i> , 2012, 8, 38-43.	0.2	0
104	Study of mutational status of Sicilian GISTs patients. <i>Annals of Oncology</i> , 2015, 26, vi31.	1.2	0
105	Petals and thorns in programmed death ligand 1 testing: Is all non-small cell lung cancer diagnostic material suitable?. <i>Cancer Cytopathology</i> , 2018, 126, 817-818.	2.4	0
106	Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future. , 2021, , .		0
107	Role of antiemetic prophylaxis for breast cancer (BC) patients treated with anti-HER2 or anti-VEGF monoclonal antibodies.. <i>Journal of Clinical Oncology</i> , 2014, 32, e20705-e20705.	1.6	0
108	Eribulin (E) and capecitabine (C), a combined treatment schedule in elderly metastatic breast cancer (EMBC): Efficacy and safety evaluation (E&S).. <i>Journal of Clinical Oncology</i> , 2014, 32, e20513-e20513.	1.6	0

#	ARTICLE	IF	CITATIONS
109	VIPoma and PPoma. , 2015, , 223-231.		0
110	Targeted Therapies for Colorectal Cancer. Current Clinical Pathology, 2015, , 147-162.	0.0	0
111	Multi-istitutional study of the evaluation of eribulin (E) use in Sicily in metastatic breast cancer (MBC): A prospective registry (VESPRY trial).. Journal of Clinical Oncology, 2015, 33, e12023-e12023.	1.6	0
112	Combination of eribulin (E) and capecitabine (C) in elderly metastatic breast cancer (MBC): Update of a new option suitable in older elderly.. Journal of Clinical Oncology, 2015, 33, 9540-9540.	1.6	0
113	The role of second-line tyrosine kinase inhibitor monotherapy in EGFR wild-type advanced non-small-cell lung cancer patients: Findings from a retrospective analysis.. Journal of Clinical Oncology, 2015, 33, e19030-e19030.	1.6	0
114	KRAS and BRAF as prognostic biomarkers in patients undergoing surgical resection of colorectal cancer liver metastasis: A systematic review and meta-analysis.. Journal of Clinical Oncology, 2016, 34, 3565-3565.	1.6	0
115	Abstract 1855: Role of mTOR inhibition in triple-negative breast cancer. , 2016, , .		0
116	The interplay between PD-L1 and vimentin in NSCLC patients: An exploratory analysis.. Journal of Clinical Oncology, 2019, 37, e20688-e20688.	1.6	0